Nasdaq
$5.59▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $334.4MShares out 59.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
14- 10.2After-hours26.10.03 05:304Ownership#●●●
Orchestra BioMed Holdings, Inc.
Insider Sherman Darren of Orchestra BioMed Holdings, Inc. filed a Form 4 statement on October 2, 2026, reporting changes in beneficial ownership as of October 1, 2026. This filing reflects changes in insider holdings and does not indicate any direct changes to the company's capital structure or financial position.…more
$5.59+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.1Regular26.10.01 23:37144Ownership
Orchestra BioMed Holdings, Inc.
Darren Sherman, an insider at Orchestra BioMed Holdings, Inc., has filed a Form 144 to report the proposed sale of company shares. This is a standard filing disclosing an insider's plan to dispose of their holdings.…more
$5.59+0.00%vs prev closeView filingShare - 10.1Pre-market26.10.01 21:148-KKey event
Orchestra BioMed Holdings, Inc.
Orchestra BioMed has surpassed its enrollment target for the 'BACKBEAT' global pivotal trial of AVIM therapy, with 330 patients randomized compared to the target of 316. The company plans to submit primary endpoint results for presentation at a major cardiovascular conference in Q2 2027, followed by marketing application submissions to the FDA and other global regulators by its partner, Medtronic.…more
$5.59+0.00%vs prev closeView filingShare
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.22 21:30#●●●#●●●
Orchestra BioMed to Host R&D Day
Orchestra BioMed will host an R&D Day on November 12 to discuss clinical progress and development plans for its key therapies. The event will highlight the clinical and commercial potential of AVIM Therapy and Virtue SAB.…more
$5.59+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.1Pre-market26.10.01 21:00
●●●●●●●● ●●●●● ●●●●●●
Orchestra BioMed has surpassed its enrollment target for the global pivotal trial of its AVIM hypertension therapy in collaboration with Medtronic. The company expects to present primary endpoint data in the second quarter of 2027, pending further regulatory milestones.…more
$5.59+0.00%vs prev close - 9.16Pre-market26.09.16 21:30
●●●●●●●● ●●●●● ●●●●●●
Orchestra BioMed will present its AVIM therapy for hypertension at the upcoming HRX Live 2026 conference. The sessions will highlight the company's strategic collaboration with Medtronic, though this remains a clinical development update rather than a direct financial catalyst.…more
$5.59+0.00%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report